Filter
Retatrutide is a next-generation investigational peptide developed to target three key metabolic hormone pathways simultaneously —
GLP-1, GIP, and glucagon receptors — to deliver unmatched results in weight management, metabolic control, and overall wellness
support. Its unique triple-agonist mechanism is designed to optimize appetite regulation, boost energy expenditure, and improve glycemic
balance more effectively than traditional single- or dual-hormone therapies.
Key Benefits
• Substantial Weight Loss: Up to ~24% body-weight reduction in clinical studies.
• Enhanced Metabolic Health: Improved insulin sensitivity, reduced fasting glucose, and decreased HbA1c.
• Liver Health: Up to 81–86% reduction in liver fat content.
• Comprehensive Wellness: Favourable changes in adiponectin, leptin, triglycerides, and waist circumference.
Clinical Highlights
• Study: 48-week, double-blind, placebo-controlled Phase 2 trial
• Results: ~22.8% weight loss (8 mg dose), ~24.2% weight loss (12 mg dose)
• ~0.9% HbA1c reduction
• Significant improvements in cardiometabolic risk factors
Safety & Tolerability
• Most common side effects: nausea, vomiting, diarrhea, abdominal discomfort, constipation — typically mild to moderate and
dose-dependent.
• Serious adverse events: Rare and comparable to placebo when dosing is titrated gradually.
• Ongoing monitoring recommended for pancreatitis, gallbladder events, or potential long-term effects.
Dosing
• Administered as a once-weekly subcutaneous injection.
• Studied doses: 1 mg, 4 mg, 8 mg, 12 mg.
• Optimal results seen at 8 mg–12 mg with titration to improve tolerability.
• No approved dosing regimen currently exists — investigational use only.
For research and informational purposes only – not for medical use.
| VALUE | 10mg, 20mg, 30mg, 50mg |
|---|
Reviews
There are no reviews yet.